Loading...
XNYS
EVH
Market cap445mUSD
Oct 08, Last price  
3.96USD
1D
-4.35%
1Q
-32.65%
Jan 2017
-73.24%
IPO
-79.23%
Name

Evolent Health Inc

Chart & performance

D1W1MN
XNYS:EVH chart
P/E
—
P/S
0.24
EPS
—
Div yield, %
—
Shrs. gr., 5y
6.10%
Rev. gr., 5y
15.20%
Revenues
1.88b
-26.56%
8,346,00025,671,000096,878,000254,188,000434,950,000627,063,000687,122,000924,639,000907,957,0001,352,013,0001,963,896,0002,554,741,0001,876,229,000
Net income
-535m
L+767.39%
-19,263,00020,023,000-25,246,000332,494,000-159,742,000-60,665,000-52,658,000-301,971,000-334,246,000-37,601,000-19,164,000-113,040,000-61,623,000-534,510,000
CFO
39m
+107.00%
-12,767,000-13,629,000-75,094,000-19,829,000-35,510,000-27,958,000-20,651,000-42,645,000-16,225,00038,747,000-11,553,000142,582,00018,765,00038,843,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Evolent Health, Inc., a prominent healthcare firm, operates through its subsidiary, Evolent Health LLC, to furnish clinical and administrative solutions to both healthcare payers and providers across the United States. Its operations are divided into two principal segments: Evolent Health Services and Clinical Solutions. The Evolent Health Services division delivers an integrated platform encompassing both administrative and clinical functions, specifically designed for health plan management and the oversight of population health. This includes essential financial and administrative support, such as managing health plan operations, risk assessment, robust analytics and reporting, and strategic leadership. A cornerstone of this segment is "Identifi," its proprietary technology, which intelligently aggregates and analyzes data, streamlines care workflows, and actively engages patients, all with the aim of achieving patient-centered and cost-effective population health outcomes. Conversely, the Clinical Solutions segment specializes in offering sophisticated care management services for various stakeholders involved in specialty care delivery. These services are crucial for organizations transitioning from traditional fee-for-service models to value-based care, accommodating their unique stage of development and prevailing market dynamics, particularly in the fields of oncology and cardiology. The overarching objective of this segment is a holistic improvement in the total cost of care. Founded in 2011, Evolent Health, Inc. maintains its corporate headquarters in Arlington, Virginia.

Related entities

Subsidiaries
EVOLENT HEALTH INTERNATIONAL PRIVATE LIMITED

Key people

Richard Jelinek
Independent Chairman of the Board · since 2025
Daniel Mccarthy
President · since 2022
Seth Blackley
Chief Executive Officer, Co-Founder, Director · since 2020
John Johnson
Chief Financial Officer · since 2019
Mario Ramos
Chief Financial Officer · since 2026
Katie DiPerna
Chief Operating Officer · since 2025
Emily Rafferty
Chief Operating Officer · since 2023
Aammaad Shams
Chief Accounting Officer · since 2022
Jonathan Weinberg
General Counsel · since 2014
Director · since 2025
Toyin Ajayi
Independent Director · since 2023
Independent Director · since 2020
Russell Glass
Independent Director · since 2024
Peter Grua
Independent Director · since 2020
Kim Keck
Independent Director · since 2021
Independent Director · since 2025
Brendan Springstubb
Independent Director · since 2025
IPO date
Jun 05, 2015
Employees
5,100
Domiciled in
US
Incorporated in
US
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
800 North Glebe Road
Suite 500
Arlington, VA 22203
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT